Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1–Infected Children in Rwanda
- 1 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 60 (4) , 400-404
Abstract
This study evaluated mid-dosing interval efavirenz plasma concentrations and the influence of CYP2B6 polymorphisms in relation to efficacy, tolerability, and adherence in 97 Rwandan HIV-infected children (3–16 years). Plasma drug concentrations and CYP2B6 polymorphisms were determined. Ten children were excluded for nonadherence. Large intersubject variability in efavirenz plasma concentrations was found. Of the 87 remaining, efavirenz concentrations were therapeutic, supratherapeutic, and subtherapeutic in 67%, 20%, and 14%, respectively. No associations were found between efavirenz concentrations and central nervous system disturbances or virologic failure. Minor allele frequencies were 0.32 (516G>T), 0.33 (785A>G), and 0.09 (983T>C). Polymorphisms in CYP2B6 were strongly associated with high efavirenz levels.Keywords
This publication has 24 references indexed in Scilit:
- Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group StudyThe Journal of Infectious Diseases, 2010
- A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single‐dose efavirenz population pharmacokinetics in UgandansBritish Journal of Clinical Pharmacology, 2009
- Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral TherapyThe Pediatric Infectious Disease Journal, 2009
- Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African AmericansThe Journal of Infectious Diseases, 2009
- Intra-Individual Variability in Efavirenz Plasma Concentrations Supports Therapeutic Drug Monitoring Based on Quarterly Sampling in the First Year of TherapyTherapeutic Drug Monitoring, 2008
- Psychosis in a 12-Year-Old HIV-Positive Girl with an Increased Serum Concentration of EfavirenzClinical Infectious Diseases, 2007
- Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphismBritish Journal of Clinical Pharmacology, 2005
- Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatographyJournal of Chromatography B, 2005
- Intrapatient Variability of Efavirenz Concentrations as a Predictor of Virologic Response to Antiretroviral TherapyAntimicrobial Agents and Chemotherapy, 2004
- Population pharmacokinetic meta-analysis with efavirenzInt. Journal of Clinical Pharmacology and Therapeutics, 2002